Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

The safety, efficacy, and pharmacokinetics of copanlisib were evaluated in this phase Ib/II study in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). The primary endpoint was safety at the recommended dose; efficacy endpoints included objective response rate (ORR), pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuhara, Noriko, Maruyama, Dai, Hatake, Kiyohiko, Nagai, Hirokazu, Makita, Shinichi, Kamezaki, Kenjiro, Uchida, Toshiki, Kusumoto, Shigeru, Kuroda, Junya, Iriyama, Chisako, Yanada, Masamitsu, Tsukamoto, Norifumi, Suehiro, Youko, Minami, Hironobu, Garcia-Vargas, Jose, Childs, Barrett H., Yasuda, Masanobu, Masuda, Shigeo, Tsujino, Toshiaki, Terao, Yui, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813077/
https://www.ncbi.nlm.nih.gov/pubmed/36175779
http://dx.doi.org/10.1007/s12185-022-03455-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813077/
https://www.ncbi.nlm.nih.gov/pubmed/36175779
http://dx.doi.org/10.1007/s12185-022-03455-0

Ejemplares similares